Intrua Financial LLC Has $1.99 Million Stake in Pfizer Inc. $PFE

Key Points

• Intrua Financial LLC raised its stake in Pfizer Inc. by 17.4% in the first quarter, owning a total of 78,392 shares valued at approximately $1.986 million.
• Pfizer reported a Q2 earnings of $0.78 per share, exceeding estimates by 20 cents, with revenue increasing 10.3% year-over-year to $14.65 billion.
• The biopharmaceutical company announced a quarterly dividend of $0.43 per share, which represents a 7.0% yield with a payout ratio of 91.49%.

Intrua Financial LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,392 shares of the biopharmaceutical company's stock after acquiring an additional 11,643 shares during the period. Intrua Financial LLC's holdings in Pfizer were worth $1,986,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PFE. William B. Walkup & Associates Inc. grew its holdings in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co grew its holdings in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC grew its holdings in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the period. MSH Capital Advisors LLC grew its holdings in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after purchasing an additional 485 shares during the period. Finally, Signature Estate & Investment Advisors LLC grew its holdings in Pfizer by 2.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock worth $488,000 after purchasing an additional 486 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

PFE stock traded down $0.95 during mid-day trading on Friday, hitting $23.91. 81,158,118 shares of the company were exchanged, compared to its average volume of 34,996,196. The business has a 50 day simple moving average of $24.79 and a 200-day simple moving average of $24.30. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $135.94 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the business earned $0.60 earnings per share. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of research firms recently commented on PFE. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.